This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Unigene's Licensee, Tarsa Therapeutics, Reports Positive Clinical Data In Phase 2 Study Of Oral Calcitonin For Prevention Of Postmenopausal Osteoporosis

BOONTON, N.J., Oct. 16, 2012 /PRNewswire/ --  Unigene Laboratories, Inc. (OTCBB: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics, today announced that its licensee, Tarsa Therapeutics, reported that a Phase 2 trial of its oral recombinant salmon calcitonin in the prevention of postmenopausal osteoporosis was successfully concluded and yielded statistically significant, clinically relevant improvements in bone mineral density (BMD) at the lumbar spine.

The Phase 2 trial evaluated the ability of Tarsa's oral calcitonin tablet to improve BMD at the lumbar spine after one year of daily treatment in postmenopausal women with low bone mass (osteopenia) at increased risk of fracture.  Tarsa's oral calcitonin was superior to placebo in increasing BMD at the lumbar spine in this patient population, and its safety profile did not differ substantially from that of placebo. The Phase 2 study results were the subject of an oral presentation at the American Society for Bone and Mineral Research (ASBMR) 2012 Annual Meeting.

Ashleigh Palmer, Chief Executive Officer, stated, "We are delighted with the positive results from Tarsa's study of oral calcitonin in postmenopausal women with osteopenia.  The safety and efficacy data in this Phase 2 study confirm the positive results that Tarsa achieved in its Phase 3 study of oral calcitonin for the treatment of postmenopausal osteoporosis."

Separately, on Friday, October 12, Tarsa announced an agreement in principle with Therapicon ® Slr to provide consulting assistance to the Italian firm in its appeal of the recent recommendation by the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) to limit the use of calcitonin-containing medicines. Therapicon's request for a reexamination of the recommendation has been acknowledged by the CHMP, and a timetable for the reexamination process has been set.

A poster presentation hosted by Tarsa at ASBMR 2012 discussed combined safety data from Tarsa's two recent year-long clinical trials of its oral calcitonin showing that no signal of carcinogenicity was detected.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs